BioMerieux SA (BMXMF)
101.91
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
BioMerieux Price to Book Value: 2.903 for May 17, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 2.903 |
| May 16, 2024 | 2.903 |
| May 15, 2024 | 3.033 |
| May 14, 2024 | 3.033 |
| May 13, 2024 | 3.033 |
| May 10, 2024 | 3.033 |
| May 09, 2024 | 3.033 |
| May 08, 2024 | 3.033 |
| May 07, 2024 | 3.026 |
| May 06, 2024 | 3.026 |
| May 03, 2024 | 3.026 |
| May 02, 2024 | 2.939 |
| May 01, 2024 | 2.939 |
| April 30, 2024 | 3.010 |
| April 29, 2024 | 3.010 |
| April 26, 2024 | 3.010 |
| April 25, 2024 | 3.011 |
| April 24, 2024 | 3.011 |
| April 23, 2024 | 3.011 |
| April 22, 2024 | 2.991 |
| April 19, 2024 | 2.991 |
| April 18, 2024 | 2.939 |
| April 17, 2024 | 3.162 |
| April 16, 2024 | 3.162 |
| April 15, 2024 | 3.179 |
| Date | Value |
|---|---|
| April 12, 2024 | 3.120 |
| April 11, 2024 | 3.169 |
| April 10, 2024 | 3.191 |
| April 09, 2024 | 3.283 |
| April 08, 2024 | 2.930 |
| April 05, 2024 | 2.930 |
| April 04, 2024 | 3.020 |
| April 03, 2024 | 3.092 |
| April 02, 2024 | 3.092 |
| April 01, 2024 | 3.092 |
| March 28, 2024 | 3.092 |
| March 27, 2024 | 3.092 |
| March 26, 2024 | 3.092 |
| March 25, 2024 | 3.092 |
| March 22, 2024 | 3.092 |
| March 21, 2024 | 3.092 |
| March 20, 2024 | 3.092 |
| March 19, 2024 | 3.092 |
| March 18, 2024 | 3.092 |
| March 15, 2024 | 3.092 |
| March 14, 2024 | 3.092 |
| March 13, 2024 | 3.092 |
| March 12, 2024 | 3.092 |
| March 11, 2024 | 3.092 |
| March 08, 2024 | 3.063 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.560
Minimum
Sep 30 2022
7.518
Maximum
Oct 12 2020
4.226
Average
4.088
Median
Jul 29 2021
Price to Book Value Benchmarks
| DBV Technologies SA | 1.005 |
| Cellectis SA | 2.540 |
| PHAXIAM Therapeutics SA (DELISTED) | 0.4731 |
| Genfit SA | 2.495 |
| Innate Pharma SA | 3.818 |
Price to Book Value Related Metrics
| PE Ratio | 31.26 |
| PS Ratio | 3.041 |
| Price to Free Cash Flow | 105.00 |
| Price | 101.91 |
| Earnings Yield | 3.20% |
| Market Cap | 12.04B |
| Operating PE Ratio | 19.67 |
| Normalized PE Ratio | 24.21 |